Detection of additional occult malignancy through profiling of ctDNA in late-stage cancer patients

Ann Oncol. 2021 Dec;32(12):1642-1645. doi: 10.1016/j.annonc.2021.09.002. Epub 2021 Sep 9.

Authors

M Aldea¹, L Cerbone², A Bayle³, C Parisi², C Sarkozy³, D Vasseur⁴, L Verlingue³, F Blanc-Durand², F Mosele², M Sakkal¹, S Ponce³, P Lavaud², Y Loriot², A Hollebecque³, C Massard³, J-C Soria⁵, L Lacroix⁴, E Rouleau⁴, A Italiano⁶

Affiliations

¹ Department of Medicine, Gustave Roussy, Villejuif, France; Drug Development.
² Department of Medicine, Gustave Roussy, Villejuif, France.
³ Drug Development.
⁴ Biopathology, Gustave Roussy, Villejuif, France.
⁵ Drug Development; Faculty of Medicine, University of Paris Saclay, Paris, France.
⁶ Drug Development; Faculty of Medicine, University of Bordeaux, Bordeaux, France. Electronic address: antoine.italiano@gustaveroussy.fr.

PMID: 34509616
DOI: 10.1016/j.annonc.2021.09.002

No abstract available

Publication types

Letter

MeSH terms

Biomarkers, Tumor / genetics
Circulating Tumor DNA* / genetics
Humans
Neoplasms* / diagnosis

Substances

Biomarkers, Tumor
Circulating Tumor DNA